| | | | | | | | | | |
|
|
| Dockets Entered
On May 23, 2005
Table of Contents
|
|
|
|
|
|
|
| Docket #
|
| Title
|
|
|
|
|
| 2000N-0504
|
| Egg Safety Action Plan
|
|
|
| 2000P-1322
|
| Food Labeling and Allergen Contamination Control
|
|
|
| 2001N-0548
|
| Guidelines for Voluntary Nutrition Labeling of Raw Fruits
|
|
|
| 2001P-0075
|
| Switch Status of Emergency Contraceptives from Rx to OTC
|
|
|
| 2001P-0345
|
| Listing the color additive yellow #5 for use in food/Drug
|
|
|
| 2002D-0325
|
| Polyvinychloride using Plasticier di-(2-ethyhexyl)phthalate
|
|
|
| 2002N-0278
|
| Bioterrorism; Prior Notice of Imported Food Shipments
|
|
|
| 2002P-0317
|
| Recall Aspartame as a Neurotoxic Drug
|
|
|
| 2003N-0076
|
| Food Labeling: Trans Fatty Acids in Nutrition Labeling; Consumer research to consider possible footnote statements
|
|
|
| 2004N-0456
|
| Serving Sizes of Products that Can Reasonably be Consumed at One Eating Occasion; Updating of Reference Amounts Customarily Consumed; Approaches for Recommending Smaller Portion Sizes
|
|
|
|
| 2004N-0527
|
| Medical Devices; Medical Device Reporting
|
|
|
| 2004N-0559
|
| Overall benefit to risk considerations for Cox-2 selective nonsteroidal anti-inflammatory drugs and related agents
|
|
|
| 2004P-0349
|
| Action on Products containing added Mercury
|
|
|
| 2005D-0047
|
| Guidance for Industry: Considerations for Plasmid DNA Vaccines for Infectious Disease Indications
|
|
|
| 2005P-0139
|
| withdrawal of approvals of certain herdwide/flockwide uses of critically and highly important antibiotics pursuant to guidance #152
|
|
|
| 2000N-0504
|
| Egg Safety Action Plan
|
|
|
| EMC
1907
|
| Michael Foods Egg Products Company
|
| Vol #:
|
| 31
|
|
|
| 2000P-1322
|
| Food Labeling and Allergen Contamination Control
|
|
|
| EMC 543
|
| A. Downs
|
| Vol #:
|
| 30
|
|
|
| 2001N-0548
|
| Guidelines for Voluntary Nutrition Labeling of Raw Fruits
|
|
|
| EMC 14
|
| C. Klein, PhD,RD,CNSD
|
| Vol #:
|
| 3
|
|
|
| 2001P-0075
|
| Switch Status of Emergency Contraceptives from Rx to OTC
|
|
|
| EMC 14444
|
| M. Letourneau
|
| Vol #:
|
| 342
|
|
|
| EMC 14445
|
| K. Illes
|
| Vol #:
|
| 342
|
|
|
| EMC 14446
|
| D. Machado
|
| Vol #:
|
| 342
|
|
|
| 2001P-0345
|
| Listing the color additive yellow #5 for use in food/Drug
|
|
|
| EMC 1262
|
| R. Evans
|
| Vol #:
|
| 5
|
|
|
| EMC 1263
|
| C. Hunsucker, RN, BSN
|
| Vol #:
|
| 5
|
|
|
| EMC 1264
|
| No signature
|
| Vol #:
|
| 5
|
|
|
| 2002D-0325
|
| Polyvinychloride using Plasticier di-(2-ethyhexyl)phthalate
|
|
|
| EMC 215
|
| S. Bakal
|
| Vol #:
|
| 4
|
|
|
| 2002N-0278
|
|
| | | | | | | | |
|
|
| Bioterrorism; Prior Notice of Imported Food Shipments
|
|
|
| EMC
229
|
| Montreal, Maine & Atlantic Railway Limited et al.
|
| Vol #:
|
| 30
|
|
|
| EMC
230
Attachment
|
| Express Delivery & Logistics Assn (XLA)
|
| Vol #:
|
| 30
|
|
|
| 2002P-0317
|
| Recall Aspartame as a Neurotoxic Drug
|
|
|
| EMC 460
|
| Mission Possible International
|
| Vol #:
|
| 7
|
|
|
| EMC 461
|
| Mission Possible International
|
| Vol #:
|
| 7
|
|
|
| EMC 462
|
| Mission Possible International
|
| Vol #:
|
| 7
|
|
|
| EMC 463
|
| Mission Possible International
|
| Vol #:
|
| 7
|
|
|
| EMC 464
|
| Mission Possible International
|
| Vol #:
|
| 7
|
|
|
| 2003N-0076
|
| Food Labeling: Trans Fatty Acids in Nutrition Labeling; Consumer research to consider possible footnote statements
|
|
|
| EMC 787
|
| No signature
|
| Vol #:
|
| 11
|
|
|
| EMC 788
|
| E. McLaughlin
|
| Vol #:
|
| 11
|
|
|
| EMC 789
|
| No signature
|
| Vol #:
|
| 11
|
|
|
| EMC 790
|
| B. Noel
|
| Vol #:
|
| 11
|
|
|
| EMC 791
|
| V. Darden
|
| Vol #:
|
| 11
|
|
|
| EMC 792
|
| I. Chang
|
| Vol #:
|
| 11
|
|
|
| EMC 793
|
| R. Kleiner
|
| Vol #:
|
| 11
|
|
|
| EMC 794
|
| E. Paviour
|
| Vol #:
|
| 11
|
|
|
| 2004N-0456
|
| Serving Sizes of Products that Can Reasonably be Consumed at One Eating Occasion; Updating of Reference Amounts Customarily Consumed; Approaches for Recommending Smaller Portion Sizes
|
|
|
|
|
|
| EMC 738
|
| R. Magnus
|
| Vol #:
|
| 4
|
|
|
| EMC 739
|
| R. Magnus
|
| Vol #:
|
| 4
|
|
|
| EMC 740
|
| D. Smith
|
| Vol #:
|
| 4
|
|
|
| EMC 741
|
| S. Pricer
|
| Vol #:
|
| 4
|
|
|
| EMC 742
|
| P. Isaacson
|
| Vol #:
|
| 4
|
|
|
| EMC 743
|
| S. D. Johnson
|
| Vol #:
|
| 4
|
|
|
| EMC 744
|
| T. Rush
|
| Vol #:
|
| 4
|
|
|
| EMC 745
|
| C. Thompson
|
| Vol #:
|
| 4
|
|
|
| EMC 746
|
| M. Burke
|
| Vol #:
|
| 4
|
|
|
| EMC 747
|
| S. Christenson
|
| Vol #:
|
| 4
|
|
|
| 2004N-0527
|
| Medical Devices; Medical Device Reporting
|
|
|
| EMC
3
|
| National Electrical Manufacturers Assn (NEMA)
|
| Vol #:
|
| 1
|
|
|
| 2004N-0559
|
| Overall benefit to risk considerations for Cox-2 selective nonsteroidal anti-inflammatory drugs and related agents
|
|
|
| EMC 29
|
| B. Leary, RN, MN, MBA
|
| Vol #:
|
| 2
|
|